de Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020–1032 (2022).

Article  PubMed  Google Scholar 

Mayer, E. A., Nance, K. & Chen, S. The gut-brain axis. Annu. Rev. Med. 73, 439–453 (2022).

Article  CAS  PubMed  Google Scholar 

Tilg, H., Adolph, T. E. & Trauner, M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 34, 1700–1718 (2022).

Article  CAS  PubMed  Google Scholar 

Silveira, M. A. D. et al. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer 8, 583–597 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, L., Huh, J. R. & Shah, K. Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine 77, 103908 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leung, C., Rivera, L., Furness, J. B. & Angus, P. W. The role of the gut microbiota in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 13, 412–425 (2016).

Article  CAS  PubMed  Google Scholar 

Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 235–246 (2019).

Article  PubMed  Google Scholar 

Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 68, 280–295 (2018).

Article  CAS  PubMed  Google Scholar 

Park, J. W. et al. Role of microbiota-derived metabolites in alcoholic and non-alcoholic fatty liver diseases. Int. J. Mol. Sci. 23, 426 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Kang, Y., Cai, Y. & Yang, Y. The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies. Liver Cancer 11, 113–125 (2022).

Article  CAS  PubMed  Google Scholar 

Bence, K. K. & Birnbaum, M. J. Metabolic drivers of non-alcoholic fatty liver disease. Mol. Metab. 50, 101143 (2021).

Article  CAS  PubMed  Google Scholar 

Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat. Rev. Neurol. 18, 476–495 (2022).

Article  PubMed  Google Scholar 

Doifode, T. et al. The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology. Pharmacol. Res. 164, 105314 (2021).

Article  CAS  PubMed  Google Scholar 

Mao, X. Y. et al. Dietary nutrition for neurological disease therapy: Current status and future directions. Pharmacol. Ther. 226, 107861 (2021).

Article  CAS  PubMed  Google Scholar 

Yu, Y. & Zhao, F. Microbiota-gut-brain axis in autism spectrum disorder. J. Genet. Genomics 48, 755–762 (2021).

Article  CAS  PubMed  Google Scholar 

Honarpisheh, P., Bryan, R. M. & McCullough, L. D. Aging microbiota-gut-brain axis in stroke risk and outcome. Circ. Res. 130, 1112–1144 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson, C. A. et al. The gut microbiota in anxiety and depression - A systematic review. Clin. Psychol. Rev. 83, 101943 (2021).

Article  PubMed  Google Scholar 

Wang, S. C. et al. Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review. Int J Mol Sci. 21, (2020).

Dai, X. & Wang, B. Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease. Gastroenterol. Res. Pract. 2015, 287348 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Wang, P. Y. et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452, 1012–1016 (2008).

Article  CAS  PubMed  Google Scholar 

Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 35–56 (2019).

Article  CAS  PubMed  Google Scholar 

Muhammad, F. et al. The molecular gut-brain axis in early brain development. Int J Mol Sci 23, 15389 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin, C. R., Osadchiy, V., Kalani, A. & Mayer, E. A. The brain-gut-microbiome axis. Cell Mol. Gastroenterol. Hepatol. 6, 133–148 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Bauer, K. C. et al. Nonalcoholic fatty liver disease and the gut-liver axis: exploring an undernutrition perspective. Gastroenterology 162, 1858–1875.e1852 (2022).

Article  CAS  PubMed  Google Scholar 

Bajaj, J. S., Ng, S. C. & Schnabl, B. Promises of microbiome-based therapies. J. Hepatol. 76, 1379–1391 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brescia, P. & Rescigno, M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol. Med. 27, 844–855 (2021).

Article  CAS  PubMed  Google Scholar 

Socala, K. et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharm. Res. 172, 105840 (2021).

Article  CAS  Google Scholar 

Thompson, R. J. et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 7, 830–842 (2022).

Article  PubMed  Google Scholar 

Zhu, J. H. et al. Efficacy and safety of vibrating capsule for functional constipation (VICONS): a randomised, double-blind, placebo-controlled, multicenter trial. EClinicalMedicine 47, 101407 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Wang, X. et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res 29, 787–803 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jena, P. K., Sheng, L., Li, Y. & Wan, Y. Y. Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. Hepatobiliary Surg. Nutr. 9, 170–182 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Tan, A. H. et al. Probiotics for constipation in parkinson disease: a randomized placebo-controlled study. Neurology 96, e772–e782 (2021).

CAS  PubMed  Google Scholar 

Schmidt, K. et al. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology 232, 1793–1801 (2015).

Article  CAS  PubMed  Google Scholar 

Huang, H. et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med 12, 102 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marascio, N. et al. The role of the microbiota gut-liver axis during HCV chronic infection: a schematic overview. J Clin Med 11, 5936 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han, H. et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit. Rev. Food Sci. Nutr. 63, 1689–1706 (2023).

Article  CAS  PubMed  Google Scholar 

Kong, L. et al. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARalpha to activate the NF-kappaB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance. J. Exp. Clin. Cancer Res. 40, 18 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong, S. et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J. Hepatol. 69, 51–59 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo, W. et al. Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front. Microbiol. 13, 873160 (2022).